1 Key Insights

2 Executive summary

3 Organizations

4 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
4.1 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2017
4.2 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2030

5 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
5.1 Introduction
5.2 Classification and clinical manifestations
5.3 Signs and Symptoms
5.4 Risk factors
5.5 Pathophysiology
5.6 Diagnosis
5.6.1 Patients' history, clinical examination, and self-monitoring
5.6.2 Angiography
5.6.3 Optical coherence tomography (OCT)

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Assumptions and Rationale
6.3 Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM
6.4 United States
6.4.1 Total prevalent cases of Wet-AMD in the United States
6.4.2 Gender-specific cases of Wet-AMD in the United States
6.4.3 Age-specific cases of Wet-AMD in the United States
6.5 EU5 Countries
6.6 Germany
6.6.1 Total prevalent cases of Wet-AMD in Germany
6.6.2 Gender-specific cases of Wet-AMD in Germany
6.6.3 Age-specific cases of Wet-AMD in Germany
6.7 France
6.7.1 Total prevalent cases of Wet-AMD in France
6.7.2 Gender-specific cases of Wet-AMD in France
6.7.3 Age-specific cases of Wet-AMD in France
6.8 Italy
6.8.1 Total prevalent cases of Wet-AMD in Italy
6.8.2 Gender-specific cases of Wet-AMD in Italy
6.8.3 Age-specific cases of Wet-AMD in Italy
6.9 Spain
6.9.1 Total prevalent cases of Wet-AMD in Spain
6.9.2 Gender-specific cases of Wet-AMD in Spain
6.9.3 Age-specific cases of Wet-AMD in Spain
6.10. UK
6.10.1 Total prevalent cases of Wet-AMD in the United Kingdom
6.10.2 Gender-specific cases of Wet-AMD in the United Kingdom
6.10.3 Age-specific cases of Wet-AMD in the United Kingdom
6.11 Japan
6.11.1 Total prevalent cases of Wet-AMD in Japan
6.11.2 Gender-specific cases of Wet-AMD in Japan
6.11.3 Age-specific cases of Wet-AMD in Japan

7 KOL Views

8 Bibliography

9 Appendix
9.1 Report Methodology

10 DelveInsight Capabilities

11 Disclaimer

12 About DelveInsight

List of Tables
Table 1: Summary of Wet-AMD Market, Epidemiology, and Key Events (2017-2030)
Table 2: Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM (2017-2030)
Table 3: Total prevalent cases of Wet-AMD in the United States (2017-2030)
Table 4: Gender-specific cases of Wet-AMD in the US (2017-2030)
Table 5: Age-specific cases of Wet-AMD in the US (2017-2030)
Table 6: Total prevalent cases of Wet-AMD in Germany (2017-2030)
Table 7: Gender-specific cases of Wet-AMD in Germany (2017-2030)
Table 8: Age-specific cases of Wet-AMD in Germany (2017-2030)
Table 9: Total prevalent cases of Wet-AMD in France (2017-2030)
Table 10: Gender-specific cases of Wet-AMD in France (2017-2030)
Table 11: Age-specific cases of Wet-AMD in France (2017-2030)
Table 12: Total prevalent cases of Wet-AMD in Italy (2017-2030)
Table 13: Gender-specific cases of Wet-AMD in Italy (2017-2030)
Table 14: Age-specific cases of Wet-AMD in Italy (2017-2030)
Table 15: Total prevalent cases of Wet-AMD in Spain (2017-2030)
Table 16: Gender-specific cases of Wet-AMD in Spain (2017-2030)
Table 17: Age-specific cases of Wet-AMD in Spain (2017-2030)
Table 18: Total prevalent cases of Wet-AMD in the United Kingdom (2017-2030)
Table 19: Gender-specific cases of Wet-AMD in the UK (2017-2030)
Table 20: Age-specific cases of Wet-AMD in the UK (2017-2030)
Table 21: Total prevalent cases of Wet-AMD in Japan (2017-2030)
Table 22: Gender-specific cases of Wet-AMD in Japan (2017-2030)
Table 23: Age-specific cases of Wet-AMD in Japan (2017-2030)

List of Figures
Figure 1: Mechanism of action of CFH (in normal regulation)
Figure 2: Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM (2017-2030)
Figure 3: Total prevalent cases of Wet-AMD in the United States (2017-2030)
Figure 4: Gender-specific cases of Wet-AMD in the US (2017-2030)
Figure 5: Age-specific cases of Wet-AMD in the US (2017-2030)
Figure 6: Total prevalent cases of Wet-AMD in Germany (2017-2030)
Figure 7: Gender-specific cases of Wet-AMD in Germany (2017-2030)
Figure 8: Age-specific cases of Wet-AMD in Germany (2017-2030)
Figure 9: Total prevalent cases of Wet-AMD in France (2017-2030)
Figure 10: Gender-specific cases of Wet-AMD in France (2017-2030)
Figure 11: Age-specific cases of Wet-AMD in France (2017-2030)
Figure 12: Total prevalent cases of Wet-AMD in Italy (2017-2030)
Figure 13: Gender-specific cases of Wet-AMD in Italy (2017-2030)
Figure 14: Age-specific cases of Wet-AMD in Italy (2017-2030)
Figure 15: Total prevalent cases of Wet-AMD in Spain (2017-2030)
Figure 16: Gender-specific cases of Wet-AMD in Spain (2017-2030)
Figure 17: Age-specific cases of Wet-AMD in Spain (2017-2030)
Figure 18: Total prevalent cases of Wet-AMD in the United Kingdom (2017-2030)
Figure 19: Gender-specific cases of Wet-AMD in the UK (2017-2030)
Figure 20: Age-specific cases of Wet-AMD in the UK (2017-2030)
Figure 21: Total prevalent cases of Wet-AMD in Japan (2017-2030)
Figure 22: Gender-specific cases of Wet-AMD in Japan (2017-2030)
Figure 23: Age-specific cases of Wet-AMD in Japan (2017-2030)